NOTE: Portions of this Exhibit are the subject of a Confidential Treatment Request by the Registrant to the Securities and Exchange Commission (the “Commission”). Such portions have been redacted and are marked with a “[***]” in place of the redacted...Development and Manufacturing Agreement • August 16th, 2004 • Nanogen Inc • Laboratory analytical instruments • New Jersey
THIS DEVELOPMENT AND MANUFACTURING AGREEMENT (the “Agreement”) is executed as of this 9th day of October, 2001, by and between PRINCETON BIOMEDITECH CORPORATION, a New Jersey corporation (“PBM”), having its principal place of business at 4242 U.S. Route 1, Monmouth Junction, New Jersey 08852, and SYN.X PHARMA, INC., an Ontario corporation (“SYN.X”), having its principal place of business at 6354 Viscount Road, Mississauga, Ontario L4VIH3 Canada. PBM and SYNX are individually referred to herein as a “Party” and collectively referred to herein as the “Parties”.
ContractCross License Agreement • August 16th, 2004 • Nanogen Inc • Laboratory analytical instruments
NOTE: Portions of this Exhibit are the subject of a Confidential Treatment Request by the Registrant to the Securities and Exchange Commission (the “Commission”). Such portions have been redacted and are marked with a “[***]” in place of the redacted language. The redacted information has been filed separately with the Commission.
